Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Annovis Bio, Inc. Common Stock (NY: ANVS )

1.510 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 707
Open 1.510
Bid (Size) 1.510 (3)
Ask (Size) 1.520 (2)
Prev. Close 1.510
Today's Range 1.510 - 1.510
52wk Range 1.110 - 20.00
Shares Outstanding 13,797,242
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Here are the top movers in Monday's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill

Performance

YTD
-70.45%
-70.45%
1 Month
-18.38%
-18.38%
3 Month
-71.56%
-71.56%
6 Month
-83.68%
-83.68%
1 Year
-87.29%
-87.29%

More News

Read More
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Receives NYSE Noncompliance Notice Over Market Cap and Equity Levels
Via Investor Brand Network
Ongoing Trial Seeks to Avert Alzheimer’s Decades Before it Strikes
Via Investor Brand Network
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present Late-Stage Alzheimer’s and Parkinson’s Data at AD/PD 2025
Via Investor Brand Network
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Advances Alzheimer’s and Parkinson’s Pipeline, Launches Pivotal Phase 3 Trial
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
The Brain’s ‘Cleanup Crew’ Could Hold the Key to Alzheimer’s Treatment, Study Shows
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Present at Alzheimer’s & Parkinson’s Drug Development Summit
Via Investor Brand Network
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment
From Annovis Bio Inc.
Via GlobeNewswire
Scientists Say Brain Stimulations Hold Potential in Treating Anxiety in Parkinson’s Sufferers
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Oppenheimer Healthcare Conference
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients in Phase 3 Alzheimer’s Trial
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Closes $21M Public Offering to Advance Alzheimer’s Drug Development
Via Investor Brand Network
Top movers in Monday's session
Via Chartmill
Keep an eye on the top gainers and losers in Monday's session.
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session.
Via Chartmill
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
US Announces Plan to Combat Parkinson’s Disease Across the Country
Via Investor Brand Network
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures U.S. Patent for Acute Neurodegenerative Treatment
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.